MetaCap

PROCEPT BioRobotics Corporation (PRCT)

NASDAQ: PRCTHealth CareMedical/Dental InstrumentsUSD

24.70-1.05 (-4.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PRCT stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.02
52-week range
16.67 – 38.11
Day range
24.64 – 26.52
Volume / Avg
1.04M / 1.31M
Beta
—

52-week range

$16.67$38.11

PRCT stock today

On Nov 20, PRCT ended the session at $24.70, shedding $1.05 (4.08%), versus the S&P 500's 3.70% decline. Shares are 35.2% below their 52-week high of $38.11, set on Dec 5, 2025 and 48.2% above the 52-week low of $16.67, in the middle of the past year's range. PRCT is down 21.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 17.3%.

PROCEPT BioRobotics has posted a net loss over the last twelve months (EPS of -$2.02), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About PROCEPT BioRobotics

Company profile

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.

Industry
Medical/Dental Instruments
CEO
Mr. Larry L. Wood
Headquarters
San Jose, CA
Employees
888
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, PROCEPT BioRobotics generated $308.1 million in revenue, up 37.2% from fiscal 2024, its 5th consecutive year of revenue growth. PROCEPT BioRobotics reported a net loss of $95.6 million, compared with a loss of $91.4 million a year earlier. Gross margin was 63.7% (up from 61.1%) and operating margin -33.7%.

PROCEPT BioRobotics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$308.05M$224.50M$136.19M$75.01M$34.47M
Growth+37.22%+64.84%+81.55%+117.60%+346.72%
Net income$-95.57M$-91.41M$-105.90M$-87.15M$-59.85M
EPS (diluted)$-1.72$-1.75$-2.24$-1.96$-3.63

Analyst forecast

Forecast

Consensus (15 analysts)

hold

Avg. price target

$22.75-7.89%

  • Strong buy 2
  • Buy 3
  • Hold 9
  • Sell 0
  • Strong sell 1

Target range

Low $16.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.38 vs $-0.39
Surprise
+2.56%

PRCT news

All PRCT news

PROCEPT BioRobotics peers

Health Care sector
PRCT peer companies
CompanyPrice% ChgMarket capCompare
KMTSKestra Medical Technologies Ltd.25.10-5.75%$1.50Bvs PRCT
NVCRNovoCure Limited10.71+0.19%$1.25Bvs PRCT
INSPInspire Medical Systems Inc.55.10-2.10%$1.60Bvs PRCT
TNDMTandem Diabetes Care Inc.17.46+3.93%$1.22Bvs PRCT
XRAYDENTSPLY SIRONA Inc.8.29-2.36%$1.65Bvs PRCT
LMATLeMaitre Vascular Inc.73.61-1.67%$1.68Bvs PRCT
DRTSAlpha Tau Medical Ltd.11.76+3.93%$1.09Bvs PRCT
SIBNSI-BONE Inc.23.73-0.08%$1.07Bvs PRCT

Indexes, lists and sector

PROCEPT BioRobotics stock FAQ

What is PROCEPT BioRobotics's stock price today?

PRCT last traded at $24.70 as of Nov 20, 4:00 PM EST, down 4.08% on the day. Prices are delayed at least 15 minutes.

Who is PROCEPT BioRobotics's CEO?

Mr. Larry L. Wood is the chief executive officer of PROCEPT BioRobotics Corporation, which has about 888 employees.

What is the PRCT 52-week high?

The 52-week high for PRCT is $38.11 and the 52-week low is $16.67. The stock is currently 35.2% below its high.

Compare PRCT